Experimental Phage Therapy of Bacterial Infections
Recruitment status was Recruiting
The primary purpose of this experimental therapy is to treat, with the aid of bacteriophages, patients with non-healing postoperative wounds or bone, upper respiratory tract, urinary, or reproductive tract infections in whom extensive antibiotic therapy failed or the use of the targeted drug is contraindicated.
|Official Title:||Experimental Phage Therapy of Drug-resistant Bacterial Infections, Including MRSA Infections|
Other: Bacteriophage preparation
Bacterial infections of different tissues and organs that prove incurable by antibiotics are a serious clinical problem. Bacteriophages (phages) are bacterial viruses which attack, multiply within, and then destroy bacteria. They can efficiently destroy bacteria which have acquired resistance to antibiotics and which cause life-threatening infections. The method of treating bacterial infections using phages has been known since the beginning of the 20th century. This experimental treatment enables the use of phage preparations under the rules of a therapeutic experiment (on the basis of the respective Polish regulations) in cases where no effective available therapy exists or the use of the targeted drug is contraindicated. It is not a research study.
The phage preparations which are used in the treatment procedures contain phages from the Bacteriophage Collection of the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences in Wrocław. For each patient, specific phage preparations that are active against the pathogenic bacterial strain isolated from the patient are used for the treatment.
|Phage Therapy Unit at the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences||Recruiting|
|Wrocław, Poland, 53-114|
|Contact: Andrzej Górski, M.D. Ph.D. 48 71-3709905 firstname.lastname@example.org|
|Contact: Ryszard Międzybrodzki, M.D. Ph.D. +48 71-3709901 email@example.com|
|Principal Investigator: Andrzej Górski, M.D. Ph.D.|
|Sub-Investigator: Ryszard Międzybrodzki, M.D. Ph.D.|
|Sub-Investigator: Wojciech Fortuna, M.D.|
|Sub-Investigator: Krzysztof Szufnarowski, M.D.|
|Sub-Investigator: Zdzisław Pawełczyk, M.D.|
|Sub-Investigator: Sławomir Letkiewicz, M.D. Ph.D.|
|Sub-Investigator: Beata Weber-Dąbrowska, Ph.D.|
|Study Director:||Andrzej Górski, M.D. Ph.D.||Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences|